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Trained immunityThe BCG vaccine will, in 2021, have been in use for 100 years. Much remains to be understood, including
the reasons for its variable efficacy against pulmonary tuberculosis in adults. This review will discuss
what has been learnt about the BCG vaccine in the last two decades, and whether this new information
can be exploited to improve its efficacy, by enhancing its ability to induce either antigen-specific and/or
non-specific effects. Many factors affect both the immunogenicity of BCG and its protective efficacy, high-
lighting the challenges of working with a live vaccine in man, but new insights may enable us to exploit
better what BCG can do.
 2021 Published by Elsevier Ltd.1. The BCG vaccine is capable of inducing protection against
tuberculosis in some groups and settings
It is often stated that the BCG vaccine does not provide protec-
tion against tuberculosis. This is not true. The systematic review
published by Mangtani et al. [1] included randomised controlled
trials investigating whether BCG vaccination induced protection
against tuberculosis. BCG vaccination is protective in some age
groups and in some settings – in neonates against pulmonary
and disseminated forms of tuberculosis, and at latitudes of 40
and above it gives better protection against pulmonary disease
than in vaccinees living closer to the equator. In school age chil-
dren protection was stronger if vaccination was restricted to those
who were skin test negative to PPD using the Mantoux skin test [1].
These observations support the generally held view that exposure
to other mycobacteria can reduce the protection induced with BCG
vaccination through either masking the protection that BCG
induces, or by blocking multiplication of the live BCG thereby pre-
venting it from inducing protection [2], a consensus that has
strengthened in the last 20 years. Overall, it is not correct to say
that the BCG vaccine is unable to protect – as it can protect infants
and young children against disseminated forms of TB, and adults
against pulmonary TB in some circumstances [1]. Most of the
world’s children receive BCG vaccination with two-thirds of those
countries giving BCG vaccination estimated to have >90% vaccine
coverage [3]. BCG vaccination is recommended by the WHO to be
given shortly after birth, however, when vaccine coverage is usu-ally assessed at 1 year of age, in some settings many infants have
been vaccinated later than the WHO recommends [4,5]. It is also
clear that this wide vaccine coverage has been insufficient to con-
trol the spread of tuberculosis. Given that in 2019, there were 10
million individuals diagnosed with tuberculosis (TB) and 1.4 mil-
lion deaths [6], we need an improved TB vaccine or vaccination
regimen [7].2. BCG-induced protective immunity can be long-lived – but this
may depend on the type of immunity being measured
Another comment often made about the BCG vaccine is that it
fails to induce long-lasting immunity, generally assumed to be
mediated by classical T-cell memory. Again, this is not correct, as
despite concerns about the induction of long-term immunological
memory by BCG in mice, in certain settings, BCG can induce very
long-lived protection in man – for as long as 50–60 years in Alas-
kan natives and American Indians [8]. Although many studies have
not included longer term follow-up, the metanalysis by Abubakar
et al. [9] identified one trial and four observational studies where
protection lasted for 15 years or more. A recent retrospective
population-based cohort analysis of BCG vaccination studies in
Norway also found 58% protection against pulmonary tuberculosis
10–19 years after vaccination; however, this effect was diminished
at later time-points [10].
Such longevity might be possible for antigen-specific immune
responses as a result of antigen-specific T-cell memory but so far
there is no evidence that non-specific protection as discussed
below can last so long. The effects of non-specific trained immu-
nity have so far only been shown to last for several months andbetter
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effects might result from the epigenetic reprogramming of cells in
the bone marrow [12]. Observational studies have suggested that
longer-term non-specific effects can persist in individuals for more
than a few years after vaccination; one Danish case-cohort study
found that BCG vaccination was associated with protection against
natural deaths (but not against accidental deaths, murders or sui-
cides) for decades [13].3. BCG vaccines are variable in composition
There is evidence that different strains of the BCG vaccine can
induce varying degrees of T-cell immunity to mycobacterial or
heterologous antigens. Infant BCG vaccination studies in Uganda,
Nigeria, South Africa and Australia suggested that BCG Denmark
may induce higher proportions than BCG Bulgaria or BCG Russia
of single or multiple cytokine producing CD4+ T-cells responding
to PPD, BCG or heterologous antigens and higher cytokine produc-
tion by these cells [14–16]. In Australia, vaccination with BCG
Japan outperformed both BCG Russia and BCG Denmark in terms
of Th1 cytokine, IL-10, MCP-1 or MIP-1b production in response
to mycobacterial antigens [16]. In Brazil, not only was the extent
of cytokine production by healthy adult peripheral blood and
umbilical cord mononuclear cells different in response to BCGMor-
eau, BCG Denmark and BCG Pasteur but also the rates of apoptosis:
BCG Moreau induced the strongest cytokine production and the
greatest degree of apoptosis [17]. Collectively, these studies sug-
gest that different strains of BCG can induce differing classical
immune responses.
There are some subtleties here though: any potential strain-
specific antimycobacterial or heterologous effects of BCG might
be susceptible to confounding, such as delivery route (discussed
below) or the number of viable bacilli in the vaccine. Mycobac-
terium bovis BCG can be tricky to grow, even for experienced vac-
cine producers, and the proportion of live and dead bacilli can
vary in different vaccine batches. This makes it hard to compare
different BCG strains directly. Even if grown and prepared in
exactly the same way, which not all BCG vaccines are, the rate of
growth can also vary. A study by Biering-Sørensen et al. [18]
showed that slower growing batches resulted in greater vaccina-
tion site scarring and increased cytokine production in response
to mycobacterial or heterologous stimuli. In another study, differ-
ent strains of BCG were found to differ in proportions of viable
bacilli and to induce divergent cytokine profiles in whole blood
from newborns and adults [19]. Interestingly, the number of viable
BCG bacilli in this study correlated with levels of GM-CSF, PDGF-
AB/BB, IL-1b, TNFa and IFNc, cytokines known to have roles in
antimycobacterial and trained immunity [19], suggesting that the
viability of BCG might affect the degree of innate training. Indeed,
gamma-irradiation of BCG decreased its ability to induce trained
immunity and related cytokine production in vitro, although it
did not abolish training completely [20].
Potential influences of BCG strains on heterologous down-
stream effects may be even more difficult to capture. While in nor-
mal birth weight infants from Guinea-Bissau BCG Denmark was
associated with higher rates of scar formation compared to BCG
Russia, there was no significant difference in rates of health consul-
tations between infant groups vaccinated with these two BCG
strains [21]. In another study in Guinea-Bissau, no significant dif-
ferences in morbidity or mortality by 6 weeks of age were observed
in newborns given BCG Russia, BCG Denmark and BCG Japan [22].
This suggests that if different strains of BCG affect the non-specific
effects induced by BCG, the impact is likely to be limited, although
more studies are needed.2
In summary, whatever BCG does, live BCG usually does it better
than dead bacilli – and this includes not only protection but induc-
tion of non-specific trained immunity. Despite these differences in
immunogenicity and in composition, the different strains of BCG
were not found to be associated with protection against TB in the
Mangtani systematic review [1].
4. What has been learnt about the immunogenicity of BCG
vaccination?
If the BCG vaccine is given to either adolescents or infants in the
UK, strong T-cell responses to cross-reactive mycobacterial anti-
gens such as PPD are induced. The last two decades have largely
been the era of cytokines for measurement of immunogenicity,
with a focus on the measurement of IFNc secretion.
Comparisons of different geographic settings in a series of trials
in adolescents and young adults showed that whereas BCG vacci-
nation induced protection against pulmonary tuberculosis in the
UK, in Malawi it failed to induce any protection against tuberculo-
sis (although it did induce some protection against leprosy) [23].
PPD stimulation of diluted whole blood samples from UK adoles-
cents showed minimal IFNc production prior to BCG vaccination,
and a marked increase that was greatest at 3 but that remained
strong at 12 months following vaccination [24]. In contrast, in
Malawi most adolescents and young adults were pre-sensitised
to PPD before BCG vaccination and did not show significant
increases in response following BCG vaccination. The ability to
make a strong IFNc response in such assays is associated with
changes in DNA methylation [25]. When South African infants pro-
gressing to a diagnosis of TB were stratified into groups of high,
medium or low IFNc responders using an ELISPOT assay in which
PBMC were stimulated with BCG, the high responders showed
the slowest rate of progression to TB [26]. BCG vaccination of UK
infants can induce polyfunctional T-cells making IFNc, TNFa and
IL-2 [27], a cell type also attracting much interest as a possible cor-
relate of protection, but in a cohort of South African infants there
was no association of these responses with progression to TB dis-
ease [28]. T-cell responses are needed though, as shown by how
susceptible those with HIV infection are to M. tuberculosis infec-
tion, or the rapidly progressive infections seen in SCID mice, as well
as the increased mycobacterial growth in mice lacking the ability
to produce or respond to IFNc; in mice and in man there are similar
examples of genetic mutations in the IFNc-IL-12 axis resulting in
susceptibility to mycobacterial disease [29]. IFNc provides valu-
able information about immunogenicity and may play a role in
protection but measuring it alone has not delivered a confirmed
correlate of protection. A number of other immunological compo-
nents, such as various cell types, antibodies and cytokines have
been proposed to be associated with protection against tuberculo-
sis (Table 1), but confirmed correlates of protection are still
needed.
5. Can measuring mycobacterial growth inhibition directly
provide a better estimate of protection?
Mycobacterial growth inhibition (MGI) assays have recently
been exploited to investigate the association between immunity
and the ability to restrict mycobacterial growth following BCG vac-
cination. They can also provide a system in which the contributions
of various cells and cytokines can be dissected.
UK infants showed a marked induction of MGI following BCG
vaccination [27]. In healthy adults, historical BCG vaccination
was associated with improved mycobacterial growth inhibition
ex vivo on its own or in the presence of isoniazid or rifampicin
[30]. Interestingly, this study detected a possible association
between NK cell frequency and inhibition of mycobacterial growth,
Table 1
Immunological components associated with protection against TB.









Enhanced inhibition of BCG growth in
MGIT
BCG-vaccinated infants [27]
CD4+ central memory T-cells Enhanced inhibition of BCG growth in
MGIT
M. tuberculosis exposed uninfected individuals [34]
CD4+IFNc+TNFa+ T-cells Control of M. tuberculosis induced








Peak CD4+ and CD8+ T-cell counts
Reduction of thoracic M. tuberculosis
burden
BCG-vaccinated NHPs [54]
CD4+PD-1+KLRG1- T-cells Reduction of M. tuberculosis burden in
lungs and spleen
BCG-vaccinated mice [57]
Epigenetically reprogrammed monocytes Reduction of M. tuberculosis burden in
lungs, spleen and bone marrow
BCG-vaccinated and non-vaccinated murine parabiont and
adoptive bone marrow transplant models
[12]
NK cells Enhanced inhibition of BCG growth in
MGIT
Historically BCG-vaccinated adults [30,31]
B-cells, CXCL10+ CD14dim monocytes Enhanced inhibition of BCG growth in
MGIT
M. tuberculosis exposed uninfected individuals [34]




IFNc Control of mycobacterial infection Human and mice gene deficiencies [29]
CXCL9, CXCL10 Enhanced inhibition of BCG growth in
MGIT
M. tuberculosis exposed uninfected individuals [34]
IL-1b, TNFa, IL-6 Elevated
IL-10
aPPD-IgA
Reduction of pulmonary and
extrathoracic M. tuberculosis burden
BCG-vaccinated NHPs [59]
aAg85A-IgG Lower risk of progression to TB
disease
BCG-vaccinated infants [26]
aAM-IgG, aAM-, aLAM-IgM Enhanced survival of mice infected
with M. tuberculosis
M. tuberculosis infection in mice [103]
Improved clearance of LAM from the
circulation and spleen
Exogenous LAM challenge in mice
a19-kDa-IgG Negative correlation between DTH
responses to PPD and a19-kDa-IgG
levels
Factory workers unexposed to TB [104]
aAM-, aLAM-, aHBHA-, a16-kDa-a-crystalin-,
and aMPB83-IgG, anti-mycobacterial IgG,
IgA
Reduced susceptibility to TB or
progression to disease
Murine or NHP M. tuberculosis infection, passive serum or





DTH – delayed-type hypersensitivity
HBHA – heparin binding hemagglutinin
MPB83 – mycobacterial cell surface lipoprotein
LAM – lipoarabinomannan
NHP – non-human primate
NB: The list of studies or reviews presented in this table is not comprehensive.
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vaccinated individuals. Further analyses showed that while overall
and cytotoxic NK cell frequencies were associated with ex vivo
inhibition of mycobacterial growth in BCG-naïve individuals,
cytokine-producing NK cell responses correlated with control of
mycobacterial growth in BCG-vaccinated individuals [31]. BCG
vaccination has been shown to enhance NK cell activation and
cytokine production in response to mycobacterial or heterologous
stimuli in infants and adults, an effect that lasted 3 to 4 months
[32,33]. BCG also protected SCID mice from lethal Candida infection
with a partial role demonstrated for NK cells [33].
Activated monocytes or macrophages are considered protective
against TB and their efficiency in containing mycobacterial infec-
tions has also been explored in mycobacterial growth inhibition
assays. A study by Joosten et al. found that enhanced secretion of
CXCL9 and CXCL10 by non-classical monocytes was associated3
with greater mycobacterial growth inhibition in individuals who
were exposed to TB but not infected, compared to TB patients or
healthy controls, although central memory T-cell responses and
B-cell frequencies were also associated with control of mycobacte-
rial growth [34]. PBMCs from those exposed to TB also showed
some features consistent with innate immune training, e.g. eleva-
tion of innate immune cytokines IL-1b, TNFa or IL-6 in response
to BCG stimulation and higher CXCL10 production in response to
heterologous stimuli, although monocyte TNFa was not associated
with improved mycobacterial growth inhibition.6. Other explanations for variable responses to BCG
The complexity of measuring such vaccine-induced immune
responses in the ‘‘real world” is very considerable. Immune status
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and more [35]. Marked differences in the IFNc and broader cyto-
kine responses following in vitro stimulation of diluted whole
blood with PPD were observed between Malawian and UK infants
who were BCG vaccinated 3 or 12 months previously [36,37]. A
study of cytokine responses in diluted whole blood cultures stim-
ulated with PPD for 6 days in Ugandan infants given BCG at birth
showed the development of immune responses that peaked 4–
10 weeks post vaccination, but with considerable individual varia-
tion, and some infants failed to make a detectable cytokine
response [38]. The literature on how delaying BCG vaccination
affects the immunogenicity of BCG vaccination has not shown
any consistent improvement with delayed vaccination [39]. The
genetics of the vaccinees, other vaccines they are given, nutrition,
seasonality and more, will influence these responses. However,
certain additional factors have received more attention in the last
decade.7. Maternal influences on the response to vaccination in their
infants
Newborn infants receiving BCG vaccination should be immuno-
logically naïve, and any confounding effects of environmental or
non-tuberculous mycobacteria should not be present. However,
young infants may have an immature immune system that has
been influenced by their mothers’ immune or infection status
[40,41]. For example, latent TB infection (LTBI) in a woman might
influence how her baby responds to BCG vaccination. In Uganda,
cytokine responses in BCG-vaccinated infants showed no associa-
tion with the mothers’ LTBI status [38]. This is perhaps surprising,
as mycobacterial antigens might have crossed the placenta and
induced either sensitisation or tolerance in the infant. Other com-
mon infections, such as malaria or other parasitic infections in the
mothers during pregnancy can have broad immunomodulatory
effects on the immune system of the newborns/infants. Although
helminth infections in the mother had limited effects on the
response to BCG in Uganda [42], viral infections such as CMV alter
CD8 T-cells and rate of progression to TB in infants [26,43].
The BCG vaccination status of the mother may also have some
effects on Th2 cytokine responses in BCG vaccinated infants to M.
tuberculosis culture filtrate proteins or cord blood IL-10, IFNc or
immune cell growth factor responses to innate stimuli [42,44]. A
possible beneficial association of previous maternal immunisation
with BCG and lower rates of parent-reported infections was found
in infants at 0–3 months of age in the Danish BCG study [45], and
maternal BCG scar was also associated with lower infant mortality
risk in Guinea-Bissau [46]. Whether this reflects an as yet unknown
biological mechanism or was associated with confounding health-
care practices within a family is not clear.8. Would BCG be more protective if given by another route?
Although when first used in 1921 the BCG vaccine was given
orally, it is now given intradermally. One area of recent and active
research is whether BCG (and other novel TB vaccines) might be
more protective if given by routes other than the standard intrader-
mal route. Intradermal vaccination is tricky and well-trained staff
are needed to give intradermal vaccines such as BCG. Some coun-
tries have therefore used a multipuncture device to deliver BCG;
this has the added benefit of reducing scarring which in some cul-
tures is regarded by parents/guardians as of major importance.
For example, in Japan and South Korea BCG Japan has been deliv-
ered percutaneously with a multi-puncture device, but skin test
responses and IFNc responses to PPD in Korean children aged 4–
7 years given BCG Pasteur intradermally or BCG Tokyo by multi-4
puncture device were comparable [47]. A larger trial of BCG given
percutaneously or intradermally in South Africa found that there
was no difference in the protective efficacy of BCG given by these
routes [48,49]. A strength of this South African study was that the
same BCG strain (Japan 172) was given by both routes. Presence
of a BCG scar is often used as a proxy for BCG vaccination history,
although scars can disappear over time and not all of those vacci-
nated develop a scar. Both the presence and the size of BCG scar
in children that have received BCG vaccination has been associated
with improved survival indicating non-specific protection [50,51].
Studies in animal models have shown that BCG can be more
protective if given intravenously rather than by other routes. Early
studies in which BCG was given to non-human primates (NHPs)
were published as long ago as 1970 [52] but there has been a
recent revival of interest in giving BCG by this route. Vaccinating
Rhesus macaques by the intravenous route induced better protec-
tion than giving BCG intradermally, or intradermally with boosting
by intratracheal administration [53]. A larger study in Rhesus
macaques used positron emission tomography–computed tomog-
raphy (PET–CT) imaging with 18F-fluorodeoxyglucose, confirming
the improved protection given by intravenous BCG, and showed
that 9/10 animals given BCG intravenously failed to show any lung
lesions [54]. In another study, giving BCG to mice intravenously
was shown to alter the differentiation of haematopoietic stem
cells, promoting myelopoiesis and enhancing the activation status
of bone marrow-derived macrophages [12]. In addition, compared
to subcutaneous immunization, BCG delivered intravenously could
be detected in the bone marrow for 7 months after BCG vaccina-
tion, suggesting prolonged interaction with the immune system.
However, giving BCG intravenously in man is not likely to be prac-
tical and could induce adverse events including disseminated dis-
ease in immunosuppressed individuals.
Alternative delivery routes delivering BCG directly into the
mucosa or lungs may also be worth exploring [55]. Compared to
intravenous immunization, aerosol vaccination with BCG gave less
bacterial dissemination and reduced bacterial counts in the lungs
[56]. In mice, intranasal BCG induced better protection in the lungs
than the standard intradermal vaccination, with induction of
antigen-specific tissue-resident T-cells expressing a PD-1+ KLRG1- -
cell-surface phenotype [57]. BCG can also induce protection in mice
when given by the sublingual route [58]. In NHPs, mucosal delivery
was associated with improved Th17 cell and IL-10 responses, slower
IGRA conversion, lower pathology in the lungs and better control of
M. tuberculosis growth in the lungs or lymphoid tissues compared to
the intradermal route [59]. We still need a better understanding of
how to maximise beneficial immune responses in the lungs while
avoiding excessive immune activation.9. Do different routes of administration also affect induction of
innate training?
BCG vaccination can also induce non-specific protection against
unrelated pathogens [60,61] and reduce all-cause mortality in
infants [62–66]. Importantly, this vaccine can induce a phe-
nomenon known as ‘‘trained immunity”, resulting in epigenetic
or metabolic reprogramming of the innate immune cells and
enhanced surface marker expression or cytokine responses upon
secondary stimulation [33,67,68], suggesting that this mechanism
can contribute to the non-specific effects of BCG and protection
against infectious diseases [69]. Adults vaccinated with BCG and
then given yellow fever vaccine were shown to have reduced virae-
mia compared to BCG-naïve controls and this effect was associated
with enhanced IL-1b production [70]. Infant BCG vaccination stud-
ies in Guinea-Bissau and the UK, as well as Australia demonstrated
that production of cytokines associated with innate immunity was
H.M. Dockrell and E. Butkeviciute Vaccine xxx (xxxx) xxxenhanced in BCG vaccinated infants compared to unvaccinated
controls upon secondary stimulation with heterologous stimuli
[32,71–73]. This phenomenon is not restricted to BCG alone as
another live mycobacterial vaccine – MTBVAC has been shown to
enhance innate cytokine responses to LPS in human monocytes
and in mice to improve resistance to an otherwise lethal infection
with S. pneumoniae [74].
BCG revaccination was able to increase reversion of interferon-
gamma release assay (IGRA) positivity in South African adolescents
who had been BCG vaccinated at birth [75], which has led to
renewed interest in giving a repeat BCG vaccination. In children,
two randomised trials have provided some evidence that a repeat
BCG vaccination may reduce all-cause mortality [76]; for example,
in infants in Guinea Bissau who had received their diptheria, per-
tussis and tetanus (DPT) booster before their BCG revaccination
at 19 months, there was some evidence of a reduction in mortality
between 19 and 60 months [77]. In the South African H4/BCG trial,
it was observed that the BCG revaccinated group had a lower rate
of upper respiratory tract infections than in either the H4:IC31
group or the placebo group [75]. In an Indonesian study in which
BCG was given monthly for 3 months to elderly individuals, the
prevalence of acute respiratory infections was reduced [78]. These
studies indicate that revaccination or boosting as well as primary
vaccination with BCG may be able to induce or enhance innate
memory with beneficial effects on survival; similar effects have
also been observed with other live attenuated vaccines such as
smallpox or oral polio vaccine [76].
The route of BCG administration can affect mycobacteria-
specific immune responses and efficacy of the BCG vaccine. How-
ever, can different routes of BCG delivery affect the extent of innate
immune training? So far, most studies of BCG-dependent innate
immune training in humans have used intradermal BCG vaccina-
tion. However, recent exposure to tuberculosis has also been asso-
ciated with innate immune training, suggesting that aerosol or
mucosal interaction with mycobacteria can imprint innate
immune responses [34]. Immunising calves with aerosolised BCG
was associated with induction of trained immunity in PBMCs,
although cytokine production by alveolar macrophages was not
affected [79]. In humans, alveolar macrophages expressed lower
levels of activation markers CD11b and HLA-DR after intradermal
immunisation with BCG, although this study did not examine
BCG-dependent changes in alveolar macrophage cytokine
responses [80]. It is possible that induction of trained immunity
in the lungs might be regulated or contributed to by adaptive
immune cells, as adenovirus-dependent priming of alveolar macro-
phages in mice was found to be dependent on IFNc produced by
CD8+ T-cells in a model of S. pneumoniae infection [81].
Is this different if the BCG vaccine is delivered by other routes? In
mice, intravenous delivery of BCG induced stronger haematopoietic
cell expansion and differentiation compared to subcutaneously
injected vaccine and was capable of priming bone marrow derived
macrophages (BMDMs), enhancing their ability to controlM. tuber-
culosis growth in vitro [12]. Intradermal BCG vaccination of humans
also polarised haematopoietic stem cell differentiation intomyeloid
cells [82], suggesting that someBCGassociated changes in the innate
immune system can occur irrespective of the delivery route.
In another study, mice were vaccinated with BCG subcuta-
neously and their ability to control growth of M. tuberculosis in
the lungs was compared with other routes of immunisation: intra-
venous, intranasal, aerosol or intramuscular [83]. A protective
effect of similar extent on mycobacterial growth in the lungs was
found for most immunisation routes despite varying colony form-
ing units of BCG, except for low-dose aerosolised BCG which did
not induce protection. In subcutaneously vaccinated mice, the pro-
tection against M. tuberculosis growth in the lung was independent
of T-cell responses, suggesting that BCG mediated protection via5
innate immune cells [83]. Interestingly, depletion of neutrophils
in this model was associated with diminished protection by BCG
[83], supporting findings in humans, where intradermal BCG was
associated with a neutrophil transcriptional signature and elevated
neutrophil counts in BCG-vaccinated infants [82].
There also seem to be differences in how BCG, delivered via the
skin, affects the innate immune cells. In humans, intradermal BCG
vaccination induced a trained phenotype in monocytes in NOD2
dependent manner, enhancing accessibility of proinflammatory
genes for transcription and cytokine production upon secondary
stimulation with mycobacterial or heterologous antigens [67,82],
with similar changes happening in the NK cells [33] and NK cell
cytokine responses associated with inhibition of mycobacterial
growth years in these historically vaccinated individuals [31].
However, control of M. tuberculosis growth in lungs of subcuta-
neously BCG-vaccinated mice was not mediated by NOD2 depen-
dent pathways, monocytes or NK cells [83]. Further investigation
would be required to clarify whether these differences reflect the
influence of route of vaccine delivery or differences in human
and murine trained innate responses, as differences in regulation
of trained immunity by long non-coding RNAs in human and mur-
ine models have been reported previously [84].10. How can what we have learnt about BCG accelerate the
development of new TB vaccines?
There is a pipeline of candidate TB vaccines in development, of
varying types. Some are recombinant BCG vaccines, designed to be
safer in infants who are HIV infected, or to induce improved pro-
tection by inclusion of additional antigens from M. tuberculosis.
Some are other live mycobacterial vaccines, includingM. tuberculo-
sis itself with mutations that reduce its virulence, or environmental
non-tuberculous mycobacteria. It is likely that any issues that
affect growth of BCG bacilli in a BCG vaccine, will similarly affect
the growth of another live mycobacterial vaccine. Other vaccine
candidates include subunit or recombinant proteins in adjuvant,
which would be given as a booster vaccine following BCG vaccina-
tion, that would depend on BCG vaccination having induced an
effective primary immune response. Similarly, the vaccines that
consist of viral vectors that deliver one or more antigens, are usu-
ally intended to boost a pre-existing immune response rather than
induce a primary immune response. The TB vaccine portfolio is
therefore very dependent on what BCG vaccination does or does
not do. It may also be beneficial if primary vaccination (for exam-
ple with a live mycobacterial vaccine) can induce non-specific
innate training.
One surprising result from a recent vaccine trial of the subunit
H4 vaccine to prevent infection rather than disease, was that
repeat BCG given as the control arm, was more effective at induc-
ing reversion to IGRA-negative status than the subunit vaccine
(although neither vaccine provided significant protection against
IGRA conversion, taken as indication of M. tuberculosis infection)
[75]. This was surprising because in a number of earlier studies
performed in different settings such as Malawi [23] or Brazil
[85], there was no improvement seen with a repeat BCG vaccina-
tion although with data from a longer-term follow-up of the
BCG-REVAC trial there was some evidence that repeat BCG could
be protective in an area of Brazil with low prevalence of non-
tuberculous mycobacteria [86].11. Could inducing greater innate training improve the
protection given by BCG or these new vaccines?
Trained immunity has been associated with protection against
heterologous infections and has been implicated in the non-
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also be able to enhance the protective efficacy of new TB vaccines
[87,88]. BCG could be detected in the bone marrow 7 months after
BCG vaccination and where it could reprogram haematopoietic
stem cells (HPSCs) inducing their differentiation into epigenetically
primed myeloid cells capable of reducing growth of M. tuberculosis
[12]. In another mouse immunisation model, BCG vaccination
induced protection against M. tuberculosis in a neutrophil-
dependent manner [83]. Of interest, BCG vaccination of human
adults induced transcriptional signatures consistent with myeloid
cell differentiation or neutrophil responses, epigenetically imprint-
ing both the HPSCs and CD14+ cells [82]. Not only BCG, but the
recombinantM. tuberculosis vaccine, MTBVAC, has also been shown
to induce trained immunity in vitro, resulting in elevated produc-
tion of IL-1b, TNFa or IL-6 upon secondary stimulation [74]. BCG-
dependent enhancement of these cytokines could be exploited, as
the cytokines could act as adjuvants to induce improved Th1 or
Th17 responses that are considered protective against TB.
Mycobacterial component-based vaccines, such as RUTI have also
been shown to improve inhibition of mycobacterial growth
ex vivo in association with phenotypic changes in monocytes from
vaccinated mice [89]. Metabolites, such as fumarate, or the fungal
component b-glucan, can also induce innate immune training
in vivo [90–92]. BCG and b-glucan can induce features of trained
immunity in cells from both neonates and adults [93], suggesting
that microbial components, and metabolites might be exploited
in combination with BCG or other anti-TB vaccines to enhance
innate immunity and possibly protective T-cell responses not only
in adults, but also in neonates, the main target group for immuni-
sation against TB.
It may also be necessary to optimise vaccine regimens to max-
imise innate training. Just as for adaptive T-cell (and antibody)
responses, BCG-dependent innate training (or that induced by
other live vaccines such as MTBVAC [74] may be susceptible to
external factors, resulting in variability. In healthy adults, circadian
rhythms have been shown to modulate both heterologous and
mycobacteria-specific cytokine production, with individuals
administered BCG vaccine in the morning showing higher differ-
ences from baseline at 2 weeks or 3 months post-immunisation
than individuals vaccinated in the evening [94]. What is learnt
from BCG may help in the design of better vaccination strategies
for both tuberculosis and other diseases [95].
It is also possible that trained innate or heterologous effects of
BCG might be sex-specific, enhancing some immune responses
more in males than in females or vice versa [96,97]. It should be
noted that such effects are subtle and often result in trends rather
than large-scale effects on all-cause morbidity or mortality [98].
While neither the systematic review by the WHO SAGE committee
in 2014, nor its update in 2016 found sex-differential effects on all-
cause mortality in BCG-vaccinated infants [63,64], some recent
studies showed that beneficial effects of BCG on all-cause mortality
can be observed at different time points since vaccination in males
and females [65].
Finally, it is not fully clear for how long the effects of trained
immunity last. Some studies in healthy adults showed that
enhancement of cytokine production is transient and unlikely to
last beyond a few months after vaccination [11], although as
noted above some longer term protection may be induced [13].
However, while variability and lack of longevity of trained immu-
nity might limit prime-boost strategies, vaccines, compounds and
metabolites inducing this phenomenon could still be exploited as
adjuvants. This rationale underpins new trials of BCG vaccination
as an interim protective measure against COVID-19, for example
in front-line healthcare workers [99,100].6
12. Conclusions
The BCG vaccine has been used for almost one hundred years
but we still have a lot to understand about it [101]. BCG vaccina-
tion can induce long-lasting protection against tuberculosis, and
induces T-cell responses, but there is considerable variability in
individual responses to vaccination between and within different
settings, which may result in both BCG itself and other factors
affecting responses to vaccination [102]. Measuring growth inhibi-
tion of BCG or M. tuberculosis itself may be more informative but
we still lack proven correlates of protection. New routes of admin-
istration are being investigated such as giving BCG intravenously
or by aerosol. BCG revaccination is also attracting interest. We
need to understand better what BCG does and does not do, in order
to develop more effective vaccination regimes to protect against
tuberculosis, using either BCG, a modified BCG vaccine, or a new
TB vaccine. We also need to investigate whether increasing innate
training might enhance the efficacy of BCG vaccination. Finally,
when developing new vaccines, we need to avoid the loss of any
beneficial non-specific protective effects that BCG vaccination pro-
vides to infants.
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